Systemic treatment by inhalation of macromolecules - principles, problems, and examples

Journal of Physiology and Pharmacology

Volumn 59, Issue SUPPL. 6, 2008, Pages 53-79

  Siekmeier, R ^a,c   Scheuch, G ^b  

^a FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES   (Germany)

^b Activaero GmbH   (Germany)

^c Bundesinstitut für Arzneimittel und Medizinprodukte ^*  (Germany)

Author keywords

Aerosol therapy; Inhalation; Peptides; Proteins; Systemic treatment

Indexed keywords

2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 MORPHOLINO 4,6 PYRIMIDINEDIAMINE; 4 [[4 CARBOXYBUTYL[2 [(4 PHENETHYLBENZYL)OXY]PHENETHYL]AMINO]METHYL]BENZOIC ACID; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; ALPHA INTERFERON; ARGINYLGLYCYLASPARTIC ACID; CALCITONIN; CETRORELIX; CYCLODEXTRIN; CYCLOSPORIN A; DESMOPRESSIN; ERGOTAMINE; FOLLITROPIN; GAMMA INTERFERON; GLUCAGON; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HEPARIN; INSULIN; LEUPRORELIN; LIPOSOME; MICROSPHERE; OXYTOCIN; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PROLACTIN; PROTEINASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT HUMAN INSULIN; SURFACTANT; THYROTROPIN; UNINDEXED DRUG; VASOPRESSIN DERIVATIVE; PEPTIDE; PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AEROSOL; ANEMIA; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; ENDOMETRIOSIS; ENURESIS; FREEZE DRYING; GRANULOCYTOPENIA; GROWTH HORMONE DEFICIENCY; HEADACHE; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; HYDROPHOBICITY; HYPERVENTILATION; INFECTION; INFERTILITY; LUNG ALVEOLUS CELL TYPE 1; LUNG ALVEOLUS CELL TYPE 2; LUNG ALVEOLUS EPITHELIUM; LUNG FUNCTION; LUNG METASTASIS; MACROMOLECULE; METERED DOSE INHALER; MIGRAINE; MOLECULAR WEIGHT; NEBULIZATION; NONHUMAN; ORTHOSTATIC HYPOTENSION; OSTEOPOROSIS; PAGET BONE DISEASE; PARTICLE SIZE; POWDER INHALER; PRECOCIOUS PUBERTY; PROSTATE CARCINOMA; PROTEIN DEGRADATION; REVIEW; SHEAR STRESS; SKIN ABSORPTION; SPRAY DRYING; SYSTEMIC DISEASE; SYSTEMIC THERAPY; THERAPY EFFECT; TREATMENT RESPONSE; ABSORPTION; ANIMAL; DRUG DOSAGE FORM; DRUG EFFECT; INHALATIONAL DRUG ADMINISTRATION; LUNG ALVEOLUS; LUNG DISEASE; METABOLISM; NEBULIZER; POWDER;

ABSORPTION; ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; DOSAGE FORMS; HUMANS; LUNG DISEASES; METERED DOSE INHALERS; NEBULIZERS AND VAPORIZERS; PEPTIDES; POWDERS; PROTEINS; PULMONARY ALVEOLI;

EID: 64549117379     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Agu RU, Ugwoke MI, Armand M, Kinget R, Verbeke N. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res 2001; 2: 198-209.
2. Scheuch G, Kohlhaeufl MJ, Brand P, Siekmeier R. Clinical perspectives on pulmonary systemic and macromolecular delivery. Adv Drug Deliv Rev 2006; 58: 996-1008.
3. Scheuch G, Siekmeier R. Novel approaches to enhance pulmonary delivery of proteins and peptides. J Physiol Pharmacol 2007; 58 (Suppl 5): 615-625.
4. Niven RW. Delivery of biotherapeutics by inhalation aerosol. Crit Rev Ther Drug Carrier Syst 1995; 12: 151-231.
5. Yu J, Chien YW. Pulmonary drug delivery: Physiologic and mechanistic aspects. Crit Rev Ther Drug Carrier Syst 1997; 14: 395-453.
6. Nicod LP. Pulmonary defense mechanisms. Respiration 1999; 66: 2-11.
7. Weibel ER. Morphometry of the Human Lung. Springer-Verlag, Berlin, 1963.
8. Wolff RK. Safety of inhaled proteins for therapeutic use. J Aerosol Med 1998; 11: 197-219.
9. Patton JS, Byron PR. Inhaling medicines: Delivering drugs to the body through the lungs. Nat Rev Drug Discov 2007; 6: 67-74.
10. Patton JS, Platz RM. Routes of delivery: Case studies. (2) Pulmonary delivery of peptides and proteins for systemic action. Adv Drug Deliv Rev 1992; 8: 179-196.
11. Valente AXCN, Langner R, Stone HA, Edwards DA. Recent advances in the development of an inhaled insulin product. Biodrugs 2003; 17: 9-17.
12. Cefalu WT. Concept, strategies, and feasibility of non-invasive insulin delivery. Diabetes Care 2004; 27: 239-246.
13. Weibel ER. Morphometry of the human lung: The state of the art after two decades. Bull Eur Physiopathol Respir 1979; 15: 999-1013.
14. Dhand R. New frontiers in aerosol delivery during mechanical ventilation. Respir Care 2004; 49: 666-677.
15. Hussain A, Arnold JJ, Khan MA, Ahsan F. Absorption enhancers in pulmonary protein delivery. J Control Release 2004; 94: 15-24.
16. Kohler D, Fleischer W. Medikamente. In Theorie und Praxis der Inhalationstherapie, D Kohler, W Fleischer (eds). Arcis Verlag, München, 2000, pp. 71-99.
17. Siekmeier R, Scheuch G. Systemische Therapie mit Aerosolen. Beispiele zur pulmonalen Verabreichung von Makromolekülen zur systemischen Therapie. Atemw-Lungenkrkh 2005; 31: 391-410.
18. Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respir Care 2005; 50: 1209-1227.
19. Irngartinger M, Camuglia V, Damm M, Goede J, Frijlink HW. Pulmonary delivery of therapeutic peptides via dry powder inhalation: Effects of micronisation and manufacturing. Eur J Pharm Biopharm 2004; 58: 7-14.
20. Shoyele SA, Cawthorne S. Particle engineering techniques for inhaled biopharmaceuticals. Adv Drug Deliv Rev 2006; 58: 1009-1029.
21. Newman SP. Principles of metered-dose inhaler design. Respir Care 2005; 50: 1177-1190.
22. Byron PR, Patton JS. Drug delivery via the respiratory tract. J Aerosol Med 1994; 7: 49-75.
23. Kobayashi S, Kondo S, Juni K. Critical factors on pulmonary absorption of peptides and proteins (diffusional barrier and metabolic barrier). Eur J Pharm Sci 1996; 4: 367-372.
24. Patton JS, Trinchero P, Platz RM. Bioavailability of pulmonary delivered peptides and proteins: α-interferon, calcitonins and parathyroid hormones. J Control Release 1994; 28: 79-85.
25. Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc 2004; 1: 338-344.
26. Barnett AH. Exubera inhaled insulin: A review. Int J Clin Pract 2004; 58: 394-401.
27. Mastrandrea LD, Quattrin T. Clinical evaluation of inhaled insulin. Adv Drug Deliv Rev 2006; 58; 1061-1075.
28. Patton JS, Bukar JG, Eldon MA. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 2004; 43: 781-801.
29. Lombry C, Edwards DA, Preat V, Vanbever R. Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules. Am J Physiol Lung Cell Mol Physiol 2004; 286: L1002-L1008.
30. Sinha VR, Kaur MP. Permeation enhancers for transdermal drug delivery. Drug Dev Ind Pharm 2000; 26: 1131-1140.
31. Song Y, Wang Y, Thakur R, Meidan VM, Michniak B. Mucosal drug delivery: Membranes methodologies, and applications. Crit Rev Ther Drug Carrier Syst 2004; 21: 195-256.
32. Davis SS, Illum L. Absorption enhancers for nasal drug delivery. Clin Pharmacokinet 2003; 42: 1107-1128.
33. Edwards DA, Dunbar C. Bioengineering of therapeutic aerosols. Annu Rev Biomed Eng 2002; 4: 93-107.
34. Kobayashi S, Kondo S, Juni K. Study on pulmonary delivery of salmon calcitonin in rats: Effects of protease inhibitors and absorption enhancers. Pharm Res 1994; 11: 1239-1243.
35. Okamoto H, Todo H, Iida K, Danjo K. Dry powders for pulmonary delivery of peptides and proteins. Kona 2002; 20: 71-83.
36. Sakagami M, Byron PR. Respirable microspheres for inhalation. The potential of manipulating pulmonary disposition for improved therapeutic efficacy. Clin Pharmacokinet 2005; 44: 263-277.
37. Kobayashi S, Kondo S, Juni K. Pulmonary delivery of salmon calcitonin dry powders containing absorption enhancers in rats. Pharm Res 1996; 13: 80-83.
38. Bitonti AJ, Dumont JA, Low SC et al. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci USA 2004; 101: 9763-9768.
39. Bitonti AJ, Dumont JA. Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway. Adv Drug Deliv Rev 2006; 58: 1106-1118.
40. Dumont JA, Bitonti AJ, Clark D, Evans S, Pickford M, Newman SP. Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway. J Aerosol Med 2005; 18: 294-303.
41. Grenha A, Remunan-Lopez C, Carvalho ELS, Seijo B. Microspheres containing lipid/chitosan nanoparticles complexes for pulmonary delivery of therapeutic proteins. Eur J Pharm Biopharm 2008; 69: 83-93.
42. Koshkina NV, Waldrep JC, Roberts LE, Golunski E, Melton S, Knight V. Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res 2001; 7: 3258-3262.
43. Verschraegen CF, Gilbert BE, Loyer E et al. Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(S)-camptothecin in patients with advanced pulmonary malignancies. Clin Cancer Res 2004; 10: 2319-2326.
44. Low SC, Nunes SL, Bitonti AJ, Dumont JA. Oral and pulmonary delivery of FSH-Fc fusion proteins via neonatal Fc receptor-mediated transcytosis. Hum Reprod 2005; 20: 1805-1813.
45. Huang YY, Wang CH. Pulmonary delivery of insulin by liposomal carriers. J Control Release 2006; 113: 9-14.
46. Rudt S, Muller R. In vitro phagocytosis assay of nanoparticles and microparticles by chemiluminescence. 1. Effect of analytical parameters, particle size and particle concentration. J Control Release 1992; 22: 263-271.
47. Edwards DA, Hanes J, Caponetti G et al. Large porous particles for pulmonary drug delivery. Science 1997; 276: 1868-1871.
48. Guntur VP, Dhand R. Inhaled insulin: Extending the horizons of inhalation therapy. Respir Care 2007; 52, 911-922.
49. Köhler D. Aerosols for systemic treatment. Lung 1990; 168 (Suppl.): 677-684.
50. Laube BL. The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir Care 2005; 50: 1161-1176.
51. Thipphawong J. Inhaled cytokines and cytokine antagonists. Adv Drug Delivery Rev 2006; 58: 1089-1105.
52. Wylam ME, Ten R, Prakash UBS, Nadrous HF, Clawson ML, Anderson PM. Aerosol granulocyte-macrophage colony-stimulating factor for pulmonary alveolar proteinosis. Eur Respir J 2006; 27: 585-593.
53. Kohler D. Aerosolized heparin. J Aerosol Med 1994; 7: 307-314.
54. Scheuch G, Brand P, Meyer T et al. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects. J Physiol Pharmacol 2007; 58 (Suppl 5): 603-614.
55. Ryszka F, Dolinska B. Initial studies on the administration route of prolactin. Boll Chim Farm 2001; 140: 169-171.
56. Anderson PM, Markovic SN, Sloan JA et al. Aerosol granulocyte macrophage-colony stimulating factor: A low toxicity, lung-specific biological therapy in patients with lung metastases. Clin Cancer Res 1999; 5: 2316-2323.
57. Okumu FW, Lee RY, Blanchard JD et al. Evaluation of the AERx pulmonary delivery system for systemic delivery of a poorly soluble selective D-1 agonist, ABT-431. Pharm Res 2002; 19: 1009-1012.
58. Davison S, Thippawong J, Blanchard J et al. Pharmacokinetics and acute safety of inhaled testosterone in postmenopausal women. J Clin Pharmacol 2005; 45: 177-184.
59. Corcoran TE. Inhaled delivery of aerosolized cyclosporine. Adv Drug Deliv Rev 2006; 58: 1119-1127.
60. Iacono AT, Johnson BA, Grgurich WF et al. A randomized trial of inhaled cyclosporine in lung- transplant recipients. N Engl J Med 2006; 354: 141-150.
61. Deshpande D, Blanchard J, Srinivasan S et al. Aerosolization of lipoplexes using AERx Pulmonary Delivery System. AAPS PharmSci 2002; 4: E13.
62. Farr SJ, Otulana BA. Pulmonary delivery of opioids as pain therapeutics. Adv Drug Deliv Rev 2006; 58: 1076-1088.
63. Evgenov OV, Kohane DS, Bloch KD et al. Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation. Am J Respir Crit Care Med 2007: 176; 1138-1145.
64. Heinzer H, Mir TS, Huland E, Huland H. Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy. J Clin Oncol 1999; 17: 3612-3620.
65. Heinzer H, Huland E, Huland H. Regionale Immuntherapie beim metastasierten Nierenzellkarzinom. Urologie (A) 2002; 41: 239-248.
66. Huland E, Heinzer H. Renal cell carcinoma - innovative medical treatments. Curr Opin Urol 2004; 14: 239-244.
67. Skubitz KM, Anderson PM. Inhalational interleukin-2 liposomes for pulmonary metastases: A phase I clinical trial. Anticancer Drugs 2000; 11: 555-563.
68. Shahiwala A, Misra A. A preliminary pharmacokinetic study of liposomal leuprolide dry powder inhaler: A technical note. AAPS Pharm Sci Tech 2005; 6: E482-E486.
69. http://www.solvaypharmaceuticals-us.com/newsroom/pressreleases/0, 28488-2-0,00.htm 2005.
70. Schermuly RT, Krupnik E, Tenor H et al. Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity. Am J Respir Crit Care Med 2001; 164: 1694-1700.
71. Lauterbach R, Szymura-Oleksiak J, Pawlik D, Warchol J, Lisowska-Miszczyk I, Rytlewski K. Nebulized pentoxifylline for prevention of bronchopulmonary dysplasia in very low birth weight infants: A pilot clinical study. J Matern Fetal Neonatal Med 2006; 19: 433-438.
72. Aubin MC, Laurendeau S, Mommerot A et al. Differential effects of inhaled and intravenous sildenafil in the prevention of the pulmonary endothelial dysfunction due to cardiopulmonary bypass. J Cardiovasc Pharmacol 2008; 51: 11-17.
73. Ichinose F, Erana-Garcia J, Hromi J et al. Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Crit Care Med 2001; 29: 1000-1005.
74. Pullamsetti S, Krick S, Yilmaz H et al. Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration. Respir Res 2005; 6: 128.
75. Ichinose F, Adrie C, Hurford WE, Bloch KD, Zapol WM. Selective pulmonary vasodilation induced by aerosolized zaprinast. Anesthesiology 1998, 88: 410-416.
76. Gupta S, Moussy F, Dalby RN, Miekka SI, Bruley DF. Pulmonary delivery of human protein C and factor IX. Adv Exp Med Biol 1997; 411: 429-435.
77. Beyer S, Speich R, Fischler M, Maggiorini M, Ulrich S. Long-term experience with oral or inhaled vasodilator combination therapy in patients with pulmonary hypertension. Swiss Med Wkly 2006; 136: 114-118.
78. Gessler T, Seeger W, Schmehl T. Inhaled prostanoids in the therapy of pulmonary hypertension. J Aerosol Med 2008; Jan 16 [Epub ahead of print].
79. Önen ZP, Akkoca Yildiz Ö, Eris Gülbay B, Karabiyikoglu G. Inhaled iloprost as a long-term additional therapy to oral sildenafil in severe idiopathic pulmonary arterial hypertension. Tuberk Toraks 2006; 54: 177-181.
80. Olschewski H, Rohde B, Behr J et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest 2003; 124: 1294-1304.
81. Schermuly RT, Inholte C, Ghofrani HA et al. Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: Amplification by different type phosphodiesterase inhibitors. Respir Res 2005; 6: 76.
82. Ceglia L, Lau J, Pittas AG. Meta-analysis: Efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Ann Intern Med 2006; 145: 665-675.